Effectiveness of the Booster of SARS-CoV-2 Vaccine among Japanese Adolescents: A Cohort Study.

COVID-19 adolescent booster infection vaccination

Journal

Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355

Informations de publication

Date de publication:
12 Nov 2022
Historique:
received: 10 10 2022
revised: 07 11 2022
accepted: 08 11 2022
entrez: 24 11 2022
pubmed: 25 11 2022
medline: 25 11 2022
Statut: epublish

Résumé

Vaccination is effective in preventing COVID-19-related hospitalization among all age groups, but there is limited evidence on the effectiveness of the booster of the SARS-CoV-2 vaccine among adolescents. We analyzed the data on the status of SARS-CoV-2 infection and their vaccination profiles in adolescents aged 13-18 years in Soma city (Fukushima, Japan) (

Identifiants

pubmed: 36423011
pii: vaccines10111914
doi: 10.3390/vaccines10111914
pmc: PMC9693574
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Vaccine. 2015 Aug 26;33(36):4398-405
pubmed: 26209838
N Engl J Med. 2022 Mar 10;386(10):998-999
pubmed: 35081295
Vaccines (Basel). 2022 Sep 02;10(9):
pubmed: 36146535
N Engl J Med. 2022 Aug 11;387(6):525-532
pubmed: 35857701
N Engl J Med. 2022 Aug 11;387(6):483-485
pubmed: 35929811
Euro Surveill. 2022 Nov;27(44):
pubmed: 36330824
Brain Behav Immun. 2022 Jul;103:154-162
pubmed: 35447302
Sci Rep. 2022 Jun 23;12(1):9950
pubmed: 35739136
Lancet Child Adolesc Health. 2022 Apr;6(4):230-239
pubmed: 35143770
PLoS Med. 2022 Sep 1;19(9):e1003992
pubmed: 36048766
Lancet. 2021 Oct 16;398(10309):1407-1416
pubmed: 34619098
N Engl J Med. 2022 May 19;386(20):1899-1909
pubmed: 35353976
BMC Infect Dis. 2015 Oct 17;15:429
pubmed: 26474974
JAMA. 2022 Jun 14;327(22):2210-2219
pubmed: 35560036
JAMA. 2020 Nov 17;324(19):1939-1940
pubmed: 33064144
MMWR Morb Mortal Wkly Rep. 2022 Mar 04;71(9):347-351
pubmed: 35239637
Hum Vaccin Immunother. 2022 Dec 31;18(1):1-3
pubmed: 33625960
PLoS One. 2018 Jun 15;13(6):e0199180
pubmed: 29906276
Bioinformatics. 2018 Dec 1;34(23):4121-4123
pubmed: 29790939
Lancet Infect Dis. 2022 Sep 28;:
pubmed: 36182678
QJM. 2021 Nov 5;114(7):445-446
pubmed: 33647970
Lancet Child Adolesc Health. 2022 Apr;6(4):240-248
pubmed: 35143771
Vaccine. 2015 Sep 11;33(38):4748-55
pubmed: 26235370
Sci Rep. 2022 Aug 10;12(1):13589
pubmed: 35948626
Int J Biostat. 2011;7(1):6
pubmed: 22848188
N Engl J Med. 2022 May 19;386(20):1910-1921
pubmed: 35320659
N Engl J Med. 2022 Nov 17;387(20):1865-1876
pubmed: 36322837
JAMA Netw Open. 2021 Apr 1;4(4):e215298
pubmed: 33835179
Lancet. 2022 Apr 2;399(10332):1303-1312
pubmed: 35305296
Nat Med. 2020 Jun;26(6):818-819
pubmed: 32341581
Vaccine. 2021 Oct 15;39(43):6449-6450
pubmed: 34535315

Auteurs

Yoshika Saito (Y)

Research Division, Medical Governance Research Institute, 2-12-13-201 Takanawa, Tokyo 108-0074, Japan.

Kana Yamamoto (K)

Research Division, Medical Governance Research Institute, 2-12-13-201 Takanawa, Tokyo 108-0074, Japan.
Department of Radiation Health Management, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1247, Japan.

Morihito Takita (M)

Research Division, Medical Governance Research Institute, 2-12-13-201 Takanawa, Tokyo 108-0074, Japan.
Department of Radiation Health Management, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1247, Japan.

Masahiro Kami (M)

Research Division, Medical Governance Research Institute, 2-12-13-201 Takanawa, Tokyo 108-0074, Japan.
Soma COVID Vaccination Medical Center, 63-3 Nakamura-Kitamachi, Soma 976-8601, Japan.

Masaharu Tsubokura (M)

Department of Radiation Health Management, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1247, Japan.
Soma COVID Vaccination Medical Center, 63-3 Nakamura-Kitamachi, Soma 976-8601, Japan.
Tokyo Foundation for Policy Research, 3-2-1 Roppongi, Tokyo 106-6234, Japan.

Kenji Shibuya (K)

Soma COVID Vaccination Medical Center, 63-3 Nakamura-Kitamachi, Soma 976-8601, Japan.
Tokyo Foundation for Policy Research, 3-2-1 Roppongi, Tokyo 106-6234, Japan.

Classifications MeSH